Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT04305769 Recruiting - Clinical trials for Clostridium Difficile Infection

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

ACT
Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident cases of uncomplicated C. difficile infection (CDI) in hospitalized, or outpatient, persons aged 18 or older. Our hypothesis is that alanyl-glutamine supplementation will decrease recurrence and mortality from CDI and these outcomes will be associated with improvement of inflammatory markers and restoration of intestinal microbiota function.

NCT ID: NCT04304885 Recruiting - Joint Infection Clinical Trials

Effect of Sonication on Periprosthetic Joint Infection Treatment Strategy.

Start date: March 15, 2020
Phase:
Study type: Observational [Patient Registry]

It is not known in the literature how much sonication affects the patient's treatment. Another important issue is that the place of this method in diagnosis is not clear. The aim of this study is to contribute to the literature on this issue and to determine the sensitivity and specificity of sonication prospectively using the new definition and effect of sonication on the treatment strategy in terms of infection in patients with PJI.

NCT ID: NCT04304690 Completed - Sars-CoV2 Clinical Trials

COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic

SEROCOV
Start date: March 16, 2020
Phase: N/A
Study type: Interventional

The epidemic due to the Sars-CoV2 virus is spreading in France, without knowning precisely since when the virus has actually circulated on the territory. Data from China but also systematic samples taken from the passengers of the Diamond Princess boat also report almost 50% of asymptomatic forms of Covid-19. The medical and paramedical staff of the front-line services for the care of patients infected with Covid-19 are in fact potentially exposed to the risk of occupational contamination due to the large number of patients treated, including in the pre-epidemic phase. Therefore, and despite the application of standard protective measures, it is possible that a certain number of these personnel already have or will contract Covid-19 disease, including in its asymptomatic form.

NCT ID: NCT04304612 Recruiting - HIV Clinical Trials

A Cost Effective and Time Saving Blood Test to Detect Six Human Bloodborne Infectious Diseases

SAFE-Blood
Start date: January 1, 2020
Phase:
Study type: Observational

The consortium will develop a new in vitro diagnostic (IVD) test to screen donated blood for bloodborne infectious pathogens, saving blood banks time and costs required for analysis of mandatory pathogens. The IVD test is a multiplex immunoassay that simultaneously screens for six bloodborne infectious diseases per blood sample. In this project, a mix of diagnostic protein markers will be developed and validated to lowdown an IVD test ready for commercial scale-up and CE-IVD certification.

NCT ID: NCT04301934 Completed - Clinical trials for Urinary Tract Infections

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Randomized controlled trial to determine clinical and microbiome difference between fractional CO2 Laser and vaginal estrogen in treating patients with recurrent urinary tract infection (UTI).

NCT ID: NCT04301869 Not yet recruiting - Pleural Infection Clinical Trials

Oral Versus Intravenous Antibiotics for the Treatment of Pleural Space Infection: a Randomized Controlled Pilot Trial

Start date: May 2020
Phase: N/A
Study type: Interventional

We aim to conduct a pilot trial assessing oral versus intravenous therapy for pleural space infections.

NCT ID: NCT04298060 Not yet recruiting - Influenza Infection Clinical Trials

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

STOP-Flu
Start date: July 2020
Phase: Phase 2
Study type: Interventional

This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.

NCT ID: NCT04297488 Recruiting - HIV-infection/Aids Clinical Trials

Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

Gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving intervention will be analyzed.

NCT ID: NCT04296695 Active, not recruiting - HIV-1-infection Clinical Trials

Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

Start date: July 14, 2021
Phase: Phase 4
Study type: Interventional

The efficacy and safety of Biktarvy in Treatment-Naïve Late Presenters with HIV-1 Infection

NCT ID: NCT04296513 Completed - Clinical trials for Helicobacter Pylori Infection

Diagnosis of Gastritis, H. Pylori Infection and Atrophic Gastritis in Dyspeptic Patients

Start date: March 1, 2020
Phase:
Study type: Observational

Gastric cancer is the third most common cause of cancer-related death worldwide (1). Upper endoscopy is necessary to detect neoplastic macroscopic features at an early stage, but subtle abnormalities in the gastric mucosa are often missed or misdiagnosed (1). Helicobacter pylori (Hp) is involved in the pathogenesis of gastric diseases, such as, peptic ulcers, gastric lymphoma, and gastric cancer. Therefore, the necessity to recognize malignant gastric lesions at an early stage is imperative.